



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Hans Van Vlierberghe**

Organisation/Company: Ghent University Hospital

Country: Belgium

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2016-(current)	Gilead	HCV compounds (Harvoni, Sovaldi...)	Hepatitis C
01/2021-(current)	Roche	Tecentriq	HCC

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
05/2014-(current)	Abbvie	HCV portfolio	HCV
01/2016-(current)	J and J	Olysio	Hepatitis C
01/2016-12/2016	BMS	HCV portfolio	hepatitis C
01/2016-(current)	Novartis	Certican	immune suppression
01/2017-(current)	Intercept	Obeticholic acid	PBC, PSC, NASH
01/2021-(current)	Roche	Tecentriq	HCC

Classified as public by the European Medicines Agency

2.4 Financial interests

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
01/2011-(current)	Astellas	OSI	HCC
04/2011-(current)	Vertex	Telaprevir	HCV
06/2011-(current)	Merck	MK0007	HCV
06/2011-(current)	Achillion	ACH	HCV
10/2010-(current)	ARQule	ARQ	HCC
02/2011-(current)	Novartis	Debio	HCV
01/2012-(current)	Abbvie	DAA	HCV
01/2014-(current)	Bayer	RAS inhibitor	HCC
01/2014-(current)	Gilead	Sofosbuvir, ledipasvir	HCV
01/2014-(current)	Johnson and Johnson	Simeprevir	HCV
01/2021-(current)	Roche	Tecentriq	HCC

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Roche	Research grant
Merck	Research grant
Bayer	Research grant
Janssen (Johnson & Johnson)	Research grant
Novartis	Research grant
Sandoz Generics	Research grant
Ferring	Research grant
Gilead	Research grant
Abbvie	Research grant
Intercept	Research grant
Falk	research grant

2.8 Close family member interest

Classified as public by the European Medicines Agency

3

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

none

2.11 CAT member or alternate

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:

Hans Van Vlierberghe

Classified as public by the European Medicines Agency

DOI Form Version-number: 4

Date:	2021-02-10
-------	------------

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template